Expansion opportunity Bionique recently expanded its facility in Harrietstown, NY and completed a grand opening in 2025, signaling capacity growth and readiness to take on more GMP mycoplasma testing projects and larger client engagements.

Acquisition and backing Asahi Kasei Bioprocess Division now owns Bionique, providing financial stability, potential access to broader corporate resources, and enhanced credibility when pitching to biopharma and cell therapy clients seeking trusted testing partners.

Strategic partnerships Recent collaboration with Bionova Scientific for mycoplasma testing indicates openness to channel partnerships and combined service offerings, presenting a pathway for joint sales motions to biopharma and contract manufacturing organizations.

Broad service portfolio Bionique offers end-to-end GMP services from raw materials and master cell banks through release testing and real-time PCR, enabling cross-sell of ancillary testing services to existing biotech and gene therapy clients pursuing integrated quality assurance solutions.

Regulatory credibility Being cGMP compliant and FDA-registered, plus recognition with industry awards, strengthens competitive positioning when targeting larger mid-market and enterprise life science customers seeking validated testing partners with stringent biosafety standards.